Incidence of venous thromboembolism in users of strontium ranelate: An analysis of data from a prescription-event monitoring study in England

Drug Safety

Volumn 33, Issue 7, 2010, Pages 579-591

  Osborne, Vicki ^a,b   Layton, Deborah ^a,b   Perrio, Michael ^a,b   Wilton, Lynda ^a,b   Shakir, Saad A W ^a,b  

^a DRUG SAFETY RESEARCH UNIT   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

Author keywords

Adverse reactions; Deep vein thrombosis; Drug induced; Prescription event monitoring; Pulmonary embolism; Strontium ranelate; Venous thrombosis

Indexed keywords

STRONTIUM RANELATE; BONE DENSITY CONSERVATION AGENT; ORGANOMETALLIC COMPOUND; THIOPHENE DERIVATIVE;

AGED; ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG USE; DRUG WITHDRAWAL; FEMALE; GENERAL PRACTITIONER; HUMAN; INCIDENCE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; POISSON DISTRIBUTION; POSTMENOPAUSE OSTEOPOROSIS; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT INDICATION; UNITED KINGDOM; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; COHORT ANALYSIS; DRUG SURVEILLANCE PROGRAM; STATISTICS AND NUMERICAL DATA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DRUG PRESCRIPTIONS; ENGLAND; FEMALE; HUMANS; INCIDENCE; MALE; ORGANOMETALLIC COMPOUNDS; QUESTIONNAIRES; THIOPHENES; VENOUS THROMBOEMBOLISM;

EID: 77953548299     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11533770-000000000-00000     Document Type: Article

References (30)

1. Servier Laboratories Limited. Protelos: summary of product characteristics. Servier, 2008 Jan 23 [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/15410/SPC/Protelos/[Accessed 2010 May 12]
2. European Medicines Agency. Protelos (Strontium Ranelate): European Public Assessment Report Summary for the Public. http://www.ema.europa.eu/humandocs/ PDFs/EPAR/protelos/121604en6.pdf, Doc. Ref.: EMEA/528138/2009 [online] [Accessed 2010 May 12]
3. Halil M, Cankurtaran M, Yavuz BB, et al. Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. Ann Pharmacother 2007; 41 (1): 41-45
4. Grosso A, Douglas I, Hingorani A, et al. Post-marketing assessment of the safety of strontium ranelate: a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 2008 Nov; 66 (5): 689-694
5. Breart G, Cooper C, Meyer O, et al. Osteoporosis and ve-nous thromboembolism: a retrospective cohort study in the UK General Practice Research Database [online]. Available from URL: http://www.springerlink.com/ content/c72l383648v82320/fulltext.pdf [Accessed 2010 May 12]
6. Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003; 70: 7-30
7. Lopez JA, Kearon C, Lee AYY. Deep vein thrombosis. Hematology Am Soc Hematol Educ Program 2004; 439-456
8. Huerta C, Johansson S, Wallander MA, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167: 935-943
9. White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107: I4-8
10. Anderson F, Spencer FA. Risk factors for venous thrombo-embolism. Circulation 2003; 107: I-9-16
11. Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2000; 160: 809-815
12. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2002; 162: 1245-1248
13. Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism Study: a population-based study of the clinical epidemiology of venous thrombo-embolism. J Gen Intern Med 2006; 21: 1525-2497
14. Shakir SAW. Prescription-event monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester: John Wiley & Sons Ltd, 2007: 307-316
15. Shakir S. Causality and correlation in pharmacovigilance. In: Talbot J, Waller P, editors. Stephens' detection of new adverse drug reactions. 5th ed. Chichester: John Wiley & Sons Ltd, 2004: 329-343
16. CIOMS/WHO. International ethical guidelines for bio-medical research involving human subjects. Geneva: CIOMS, 2002
17. Royal College of Physicians of London. Guidelines on the practice of ethics committees in medical research involving human subjects. 3rd ed. London: Royal College of Physicians of London, 1996
18. General Medical Council. Frequently asked questions supplement to 'confidentiality: protecting and providing information'. London: General Medical Council, 2004: 9
19. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585-593
20. Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5 (4): 692-699
21. Tsai A, Cushman M, Rosamond W, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002 May 27; 162: 1182-1189 (Pubitemid 34522408)
22. Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 2004 Oct; 104: 837-844
23. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006 Jul 13; 355 (2): 125-137 (Pubitemid 44050394)
24. Daiichi Sankyo UK Ltd. Summary of product character-istics: Evista. Daiichi Sankyo UK Ltd, 2008 Sep 17 [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/595/SPC/Evista+60mg+film- coated+tablets/[Accessed 2010 May 12]
25. Merck Sharpe & Dohme Ltd. Summary of product char-acteristics: Fosamax. Merck Sharpe & Dohme Ltd, 2009 Apr21 [online]. Available from URL: http://www.medicines. org.uk/EMC/medicine/1175/SPC/Fosamax/[Accessed 2010 May 12]
26. Hallworth R. Prevention and treatment of postmenopausal osteoporosis. Pharm World Sci 1998; 20 (5): 198-205
27. Writing Group for the Women's Health Initiative In-vestigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002; 288 (3): 321-333
28. Meunier PJ, Roux C, Seeman E, et al. The effects of stron-tium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004 Jan 29; 350 (5): 459-468 (Pubitemid 38133766)
29. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis. Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90 (5): 2816-2822
30. Spannagl M, Heinemann L, DoMinh T, et al. Compar-ison of incidence/risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: a community-based cohort study. Thromb J 2005 Jul 20; 3: 8